Hepatitis C is a disease caused by the hepatitis C virus (HCV) that primarily affects the liver. HCV is often asymptomatic in early stages, delaying diagnosis. According to the Centers for Disease Control and Prevention, over half of the people who become infected with HCV will develop chronic infection, possibly leading to severe health issues like cirrhosis, liver cancer, and death.
Today, we’re highlighting a pair of clinical trials related to hepatitis C. These ongoing, phase 3 trials are based in the United States and are both anticipated to complete within the next year and a half.
Quick View Table of Ongoing, Phase 3, Hepatitis C Clinical Trials
| Study Title | Phase | Enrollment | Start Date | Last Update Posted |
|---|---|---|---|---|
| Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder | 3 | 92 | December 18, 2023 | April 24, 2025 |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | 3 | 880 | April 7, 2025 | June, 3, 2025 |
Ongoing Phase 3 Clinical Trials for Hepatitis C
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
- Sponsor: Atea Pharmaceuticals, Inc.
- Goal: Compare the efficacy and safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination to Sofosbuvir-Velpatasvir Fixed-dose Combination in adults with chronic Hepatitis C virus.
- Interventions: Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)
- Primary Outcome Measure: Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.
- Timeframe: Day 1 through week 24.
- Study Details
- Source
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
- Sponsor: White River Junction Veterans Affairs Medical Center
- Goal: To further investigate glecaprevir/pibrentasvir, a direct acting antiviral that has been associated with posttraumatic stress disorder symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection.
- Interventions: Glecaprevir/pibrentasvir, placebo
- Primary Outcome Measure: Clinical Administered Post-Traumatic Stress Disorder Scale version 5 (CAPS-5)
- Timeframe: Change from Baseline CAPS score at 8 weeks.
- Study Details
- Source
The C-Beyond trial has an estimated primary completion date of September 2026, with an estimated study completion later that December. The PTSD trial has an estimated primary completion date at exactly the end of this year, December 31, with an estimated study completion date of September 2026.
Sign up for alerts and stay informed on the latest clinical trials and the guidelines they impact.
Copyright © 2025 Guideline Central, all rights reserved.